Exercise for Toxicity Management in Cancer—A Narrative Review

Ian R Kleckner, Richard F Dunne, Matthew Asare, Calvin Cole, Fergal Fleming, Chunkit Fung, Po-Ju Lin, and Karen M Mustian

University of Rochester Medical Center, James P Wilmot Cancer Institute, Rochester, New York, US

DOI: https://doi.org/10.17925/OHR.2018.14.1.28

Although the treatment of cancer is more effective now than ever, patients with cancer still face acute and chronic toxicities such as fatigue, cardiotoxicity, pain, cognitive impairment, and neurotoxicity. In this narrative review, we briefly discuss the use of exercise for toxicity management in patients with cancer, biological mechanisms underlying the toxicities and the effects of exercise, barriers that patients—especially underserved patients—face in adopting and adhering to exercise programs, and new technologies to overcome barriers to exercise. Our conclusions and clinical suggestions are: (1) exercise is safe and effective for treating many toxicities; (2) patients can benefit from a variety of exercise modalities (e.g., walking, cycling, resistance bands, yoga); (3) exercise should be started as soon as possible, even before treatments begin; (4) exercise should be continued as long as possible, as a lifestyle; and (5) barriers to exercise should be identified and addressed, (e.g., continually encouraging patients to exercise, using mobile technology, advocating for safe communities that encourage active lifestyles). Future research should inform definitive clinical guidelines for the use of exercise to ameliorate toxicities from cancer and its treatment.

A growing body of literature suggests that exercise is safe, feasible, and effective in alleviating or preventing toxicities from cancer and its treatment for patients across the treatment continuum.4-7 As we review herein, dozens of randomized controlled trials (RCTs) have assessed how toxicities from cancer and its treatment are affected by a wide range of exercises, including aerobic exercises such as walking, running, and stationary cycling; resistance exercises such as supervised weight training and the use of therapeutic resistance bands; and other forms of exercise such as yoga and Tai Chi (herein referred to as Tai Chi). Exercise is effective in treating a wide range of toxicities likely due to its established beneficial effects on multiple biological pathways (e.g. inflammation, endocrine hormones, the hypothalamic-pituitary-adrenal [HPA] axis, and mitochondria), psychological pathways (e.g. improved self-worth, improved self-esteem from mastering new skills, greater sense of control, time away from stress), and social pathways (e.g. more positive social interactions via improved self-confidence, socializing during/after exercise). Section 5 reviews biological mechanisms of the toxicities and effects of exercise in more detail. Indeed, exercise can complement pharmacological therapies, which most often are selected or designed to treat a single toxicity or pathway. Exercise is

Forty percent of Americans will be diagnosed with cancer in their lifetimes. Due to continued advances in cancer detection and treatment, there are an unprecedented number of cancer survivors. In fact, the 5-year survival rate for all cancers has increased from 50% in the 1970s to 67% during the period of 2006–2012. The two most prevalent types of cancer, prostate and breast cancer, have reached a 5-year survival of 99% and 89%, respectively. Despite advances in cancer treatments that have improved overall survival, patients still face toxicities from cancer and its treatment that impair quality of life, productivity, and sometimes prohibit the use of maximally effective treatments. The National Cancer Institute (NCI) Community Oncology Research Program (NCORP) Symptom Management Committee has identified high-priority cancer- and treatment-related toxicities as areas for future research. These toxicities are divided into first and second tiers based on their potential to rapidly, significantly, and positively affect cancer care, if they are alleviated. The first tier of toxicities includes fatigue, cardiotoxicity, pain, cognitive impairment, and neurotoxicity; the second tier of toxicities includes sleep disturbances, bone damage, metabolic toxicity, and psychological distress. Table 1 describes each toxicity, its prevalence, and how it can be studied using patient report, clinical assessments, and objective biomarkers. We focused our review on the highest-priority toxicities identified by the NCORP Symptom Management Committee; and though we acknowledge the importance of other toxicities (nausea, vomiting, sexual dysfunction, hair loss, mucositis, lymphedema, etc.), they are beyond the scope of this review.

A growing body of literature suggests that exercise is safe, feasible, and effective in alleviating or preventing toxicities from cancer and its treatment for patients across the treatment continuum. As we review herein, dozens of randomized controlled trials (RCTs) have assessed how toxicities from cancer and its treatment are affected by a wide range of exercises, including aerobic exercises such as walking, running, and stationary cycling; resistance exercises such as supervised weight training and the use of therapeutic resistance bands; and other forms of exercise such as yoga and Tai Chi. Exercise is effective in treating a wide range of toxicities likely due to its established beneficial effects on multiple biological pathways (e.g. inflammation, endocrine hormones, the hypothalamic-pituitary-adrenal [HPA] axis, and mitochondria), psychological pathways (e.g. improved self-worth, improved self-esteem from mastering new skills, greater sense of control, time away from stress), and social pathways (e.g. more positive social interactions via improved self-confidence, socializing during/after exercise). Section 5 reviews biological mechanisms of the toxicities and effects of exercise in more detail. Indeed, exercise can complement pharmacological therapies, which most often are selected or designed to treat a single toxicity or pathway. Exercise is

Keywords
Side effects, toxicities, exercise, yoga, Tai Chi, mechanism, metahealth, disparities

Disclosures: Ian R Kleckner, Richard F. Dunne, Matthew Asare, Calvin Cole, Fergal Fleming, Chunkit Fung, Po-Ju Lin, and Karen M Mustian have nothing to disclose in relation to this article.

Acknowledgments: The authors would like to thank Dr Amber Kleckner for copyediting this manuscript.


Compliance with Ethics: This study involves a review of the literature and did not involve any studies with human or animal subjects performed by any of the authors.

Authorship: All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship of this manuscript, take responsibility for the integrity of the work as a whole, and have given final approval to the version to be published.

Open Access: This article is published under the Creative Commons Attribution Noncommercial License, which permits any noncommercial use, distribution, adaptation, and reproduction provided the original author(s) and source are given appropriate credit.

Received: September 29, 2017
Accepted: November 21, 2017
Citation: Oncology & Hematology Review. 2018;14(1):28-37

Corresponding Author: Ian Kleckner, Cancer Control Center, Department of Surgery, University of Rochester Medical Center, 265 Crittenden Blvd., Box CU 420658, Rochester, NY 14642, US. E: ian_kleckner@URMC.Rochester.edu

Support: Funding was provided by the National Cancer Institute, including funds from NCORP parent grant U10 CA037420, NCORP supplement U10 CA037420, and R25 CA102618.
Table 1: High-priority toxicities from cancer and its treatment

<table>
<thead>
<tr>
<th>Toxicity</th>
<th>Definition</th>
<th>Prevalence</th>
<th>Measurement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fatigue</td>
<td>Distressing, persistent, subjective sense of physical, emotional, and/or cognitive tiredness or exhaustion related to cancer or cancer treatment that is not proportional to recent physical activity and interferes with usual functioning</td>
<td>Approximately 80–100% of patients with cancer (^{153})</td>
<td>Patient-reported symptoms (e.g. fatigue rating scale, Brief Fatigue Inventory, Multidimensional Fatigue Symptom Inventory (^{153}))</td>
</tr>
<tr>
<td>Cardiotoxicity</td>
<td>Damage to the heart, leading to chest pain, shortness of breath, heart attack, and heart failure. Cardiotoxicities include cardiomyopathy, myocarditis, pericarditis, acute coronary syndromes, and congestive heart failure (^{154})</td>
<td>Approximately 27% of patients receiving the HER2-inhibitor trastuzumab (plus doxorubicin and cyclophosphamide) (^{155})</td>
<td>Patient-reported symptoms (e.g., shortness of breath)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Approximately 20–50% of patients receiving inhibitors of VEGFA (^{155})</td>
<td>Functional tests (6-minute walk test, VO(_{2}\max) test on treadmill, bicycle, etc.)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Approximately 7% of patients receiving tyrosine kinase inhibitors (^{155})</td>
<td>Biomarkers (red blood cell count, hemoglobin count, etc.)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Risk is elevated from chest radiotherapy</td>
<td></td>
</tr>
<tr>
<td>Pain</td>
<td>An unpleasant sensory and emotional experience associated with actual or potential tissue damage (^{156})</td>
<td>Approximately 59% of patients with cancer (^{157})</td>
<td>Patient-reported symptoms (e.g. pain rating scale, McGill Pain Questionnaire, Brief Pain Inventory (^{157}))</td>
</tr>
<tr>
<td>Cognitive impairment</td>
<td>Impaired learning, memory, attention, and speed of information processing (^{160})</td>
<td>Up to 75% of patients with cancer and cancer survivors (^{161})</td>
<td>Patient-reported symptoms (e.g. FACT-Cog (^{162}))</td>
</tr>
<tr>
<td>Neurotoxicity</td>
<td>Damage to nerve cells in the brain, spinal cord, or periphery (^{156})</td>
<td>Up to 68% of patients 1 month after completing neurotoxic chemotherapy (taxanes, platinum-based agents, vinca alkaloids, thalidomide, or bortezomib) (^{156})</td>
<td>Patient-reported symptoms (e.g. CIPN-20, Total Neuropathy Score (^{163}))</td>
</tr>
<tr>
<td></td>
<td>Peripheral neuropathy can cause pain, numbness, tingling, cramping, motor problems, balance impairment, and sexual dysfunction (^{164})</td>
<td>Up to 30% of patients 6 months after completion of neurotoxic chemotherapy (^{166})</td>
<td>Functional tests (tactile threshold, quantitative sensory testing, balance tests, etc.) (^{158})</td>
</tr>
<tr>
<td>Sleep disturbances</td>
<td>Impaired sleep quality or insomnia, characterized by excessive daytime napping, difficulty falling asleep, difficulty staying asleep, and waking up too early (^{166})</td>
<td>Approximately 20–70% of patients with breast cancer (^{157})</td>
<td>Patient-reported symptoms (e.g. Pittsburgh Sleep Quality Index (^{153}))</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Functional tests (actigraphy to assess physical activity and movement at night (^{157}))</td>
</tr>
<tr>
<td>Bone damage</td>
<td>Loss of bone tissue (low bone density) and loss of bone integrity (osteoporosis), leading to increased risk of fracture, morbidity, and mortality (^{177})</td>
<td>Patients receiving hormonal therapy (aromatase inhibitors, androgen deprivation) lose bone 2–10 times faster than age-matched healthy individuals (^{172})</td>
<td>Patient-reported symptoms (bone pain, etc.)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Biomarkers (DXA, bone resorption and bone formation markers (^{179}))</td>
</tr>
<tr>
<td>Metabolic toxicity</td>
<td>Appetite loss, muscle wasting or generalized weight loss (cachexia), insulin resistance, and type-2 diabetes (^{178})</td>
<td>Cachexia in 50–87% of patients with gastrointestinal, pancreatic, lung, and colorectal cancers; the prevalence is lower in patients with other cancers (^{157})</td>
<td>Patient-reported symptoms (appetite loss, etc.)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Insulin resistance and type-2 diabetes in some patients receiving androgen deprivation therapy, e.g. for prostate cancer (^{178})</td>
<td>Biomarkers (bodyweight, body composition, glucose tolerance test, ghrelin, etc.) (^{179})</td>
</tr>
<tr>
<td>Psychological distress</td>
<td>A multifactorial unpleasant experience involving psychological, social, spiritual, or physical suffering, including feelings of vulnerability, sadness, fear, depression, anxiety, panic, loneliness, and existential or spiritual crisis (^{182})</td>
<td>Approximately 15–27% pre-, during-, and post-treatment (^{161})</td>
<td>Patient-reported symptoms (Distress Thermometer, Hospital Anxiety and Depression Scale, Center for Epidemiologic Studies: Depression Scale (^{169}))</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Anxiety persists longer than depression in cancer survivors, with prevalence of approximately 27% (^{161})</td>
<td>Clinical diagnosis (e.g. Diagnostic and Statistical Manual of Mental Disorders)</td>
</tr>
</tbody>
</table>

This list only includes high priority toxicities determined by the National Cancer Institute (NCI) Community Oncology Research Program (NCORP) Symptom Management Committee. \(^{4}\)

CANTAB = Cambridge Neuropsychological Test Automated Battery; CIPN = chemotherapy-induced peripheral neuropathy; DXA = dual energy x-ray absorptiometry; FACT = Functional Assessment of Cancer Therapy; HER2 = human epidermal growth factor receptor 2; VEGFA = vascular endothelial growth factor A; VO\(_{2}\)max = aerobic fitness.

Exercise for Toxicity Management in Cancer—A Narrative Review

also feasible because it can be designed to accommodate the unique needs of each patient based on age, health status, and ability. \(^{6}\)

The goal of this paper is to present a broad narrative review of the use of exercise for toxicity management in patients with cancer. First, we review studies of exercise before cancer treatment, during cancer treatment, and after completion of cancer treatment. Next, we review biological mechanisms by which exercise exerts its beneficial effects, to better understand how it can be optimized and individualized. We review disparities in populations who have been understudied with respect to exercise during cancer as well as barriers preventing patients from exercising. Finally, we review technology to track and facilitate exercise adherence. We conclude with suggestions for clinicians to help patients select and adhere to an exercise program. This growing body of literature provides best practice suggestions in most cases,
but has not yet reached a level of evidence required to produce definitive guidelines. Our major conclusions and clinical suggestions are summarized in Table 2, with more detailed suggestions for key toxicities listed in Table 3. Our review of studies is not complete, but rather highlights RCTs of exercise, examining one of NCORP’s high-priority toxicities for studies that are particularly definitive (i.e. large sample size, rigorous study design) or particularly informative (i.e. novel measures or interventions).

Exercise before cancer treatment

Clinical exercise interventions are often aimed at promoting recovery following surgery (rehabilitation) when patients are typically physically and mentally drained following their procedure. In contrast, “prehabilitation” increases the physiological function of a patient prior to surgery, enhancing tolerance to surgery and subsequent recovery. Prehabilitation is important because poor baseline functional reserve increases the risk of postoperative complications following major surgery. The feasibility and utility of exercise as a single mode of prehabilitation has been explored in a couple of RCTs and other clinical trials in patients undergoing surgery for cancer resection. These studies ranged in sample size from 30–112, and showed beneficial effects of 2–6 weeks of aerobic exercise or aerobic plus resistance exercise on quality of life and aerobic capacity measured by an aerobic capacity (VO2max) test or 6-minute walk test. For example, one RCT in 38 patients with liver metastases from colorectal cancer showed that supervised high-intensity interval cycling of 30 minutes/session, three sessions/week for 4 weeks, improved pre-surgical VO2max and quality of life compared to standard care. In another RCT of 112 patients scheduled to receive colorectal surgery, simple walking and breathing exercises improved walking capacity (6-minute walk test) both before and after surgery, compared to a cycling and strengthening intervention. These results may be due to the fact that the walking and breathing exercises yielded better adherence than cycling and strengthening (90% versus 16%), highlighting the importance of selecting an exercise intervention that a given sample will adhere to. Together, the prior research suggests that exercise prehabilitation is a feasible, safe, and effective way to improve preoperative fitness, provided appropriate exercises are selected (left column of Table 3). However, with only a few prior studies, further research with standardized outcomes is required to determine the optimal duration and mode of delivery before definitive recommendations can be made.

Exercise during cancer treatment

There are several RCTs demonstrating that exercise is safe, feasible, and effective in mitigating most of the NCORP high-priority toxicities (Table 1) when it is prescribed concurrently with chemotherapy, hormonal therapy, or radiation therapy (middle column of Table 3).

Exercise during chemotherapy

A recent meta-analysis, systematic review, and Cochrane review found that exercise significantly reduced fatigue both during or after completion of adjuvant chemotherapy. This exercise-induced improvement in fatigue was largest in studies using only aerobic exercise, although combined aerobic plus resistance training was effective too. For example, a recent three-arm RCT of 230 patients with breast cancer receiving adjuvant chemotherapy (the Physical Exercise During Adjuvant Chemotherapy Effectiveness Study [PACES]) compared (1) usual care, (2) an unsupervised low-intensity walking program of at least 30 minutes/day, 5 days/week, and (3) conditioned plus supervised moderate- to high-intensity aerobic plus resistance exercise program of 50 minutes/session, two sessions/week. The high-intensity exercise program reduced general fatigue more than usual care, and it reduced physical fatigue more than the low-intensity walking program. Several smaller RCTs suggest that fatigue during chemotherapy can be treated using yoga, with 60 patients with breast cancer receiving either standard care or yoga performed for 60 minutes/session, two sessions/week for 8 weeks, and Tai Chi, with 96 patients with lung cancer receiving either low-impact exercise (control) or Tai Chi performed for 60 minutes/session, every other day for 12 weeks. For cardiotoxicity, the higher-intensity aerobic and resistance exercise routine in the PACES trial significantly improved endurance and maximal short exercise capacity, assessed using a graded bicycle test, compared to usual care. In a separate study of 269 patients with mixed tumor types...
### Table 3: Example studies showing beneficial effects of exercise on key toxicities from cancer and its treatment

<table>
<thead>
<tr>
<th>Toxicity</th>
<th>Exercise mode and dose shown to be effective before treatment</th>
<th>Exercise mode and dose shown to be effective during treatment</th>
<th>Exercise mode and dose shown to be effective after treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Fatigue</strong></td>
<td></td>
<td><strong>During chemotherapy:</strong> supervised exercise two sessions/week: 30 minutes aerobic exercise at 50–80% maximum workload (12–16 out of 18 for perceived exertion), plus 20 minutes resistance exercise of six large muscle groups with two sets of eight reps at 80% one-rep maximum. Patients were encouraged to be physically active 30 minutes/day for 5 days/week at home.</td>
<td>Group Gentle Hatha, Restorative, Hatha yoga for 75–120 minutes/session, two sessions/week for 4–12 weeks with breathing exercises and meditation.</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Group</strong> Gentle Hatha, Restorative, Iyengar yoga for 75–120 minutes/session, two sessions/week for 4–12 weeks with breathing exercises and meditation.54,66–68,185</td>
<td><strong>Unsupervised resistance and aerobic training.</strong> Resistance training with 10 exercises across large muscle groups at least two sessions/week at a moderate intensity using provided resistance bands. Patients gradually increased their repetitions to 15, at which point they selected a higher-resistance band. Aerobic training involved walking at a brisk pace (one mile per 20 minutes) and logging steps with a provided pedometer. Patients increased steps by 10% every other week if they achieved their prior goal.</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>During radiation:</strong> unsupervised walking 20–45 minutes/day for 3–5 days/week at 50–70% maximum heart rate for 7 weeks.47</td>
<td><strong>Neurotoxicity</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>During radiation:</strong> supervised physical therapy exercises for core strength (abdominals, hips, back) to relieve spinal bone pain.51,54</td>
<td><strong>Neurotoxicity</strong></td>
</tr>
<tr>
<td><strong>Cardiotoxicity</strong></td>
<td>High-intensity interval cycling (alternating &lt;60% VO2max and &gt;90% VO2max), 30 minutes/session, 3 sessions/week for 4 weeks.22</td>
<td><strong>During chemotherapy:</strong> see Fatigue (above).24</td>
<td><strong>Cardiotoxicity</strong></td>
</tr>
<tr>
<td><strong>Pain</strong></td>
<td></td>
<td><strong>During chemotherapy:</strong> supervised aerobic exercise (choice of cycling, treadmill, elliptical, rower, or combination) three sessions/week for 50–60 minutes/session starting 1–2 weeks before chemotherapy until 3–4 weeks after completion of chemotherapy. Intensity started at 55–60% VO2max and progressed to 70–75% VO2max by week 6. Initial duration started at 15–30 minutes/session and progressed to 50–60 minutes/session by week 6.30</td>
<td><strong>During radiation:</strong> supervised physical therapy exercises for core strength (abdominals, hips, back) to relieve spinal bone pain.51,54</td>
</tr>
<tr>
<td><strong>Cognitive</strong></td>
<td>impairment</td>
<td><strong>During myeloablative chemotherapy:</strong> aerobic and resistance training 30–40 minutes/session, five sessions/week for the duration of chemotherapy until blood cell count was normalized. Aerobic training used cycling for 10–20 minutes, with the use of interval training if steady state training intensity is too high. Three resistance exercises over 20 minutes using the main muscle groups (bridging, sit ups, back and arm exercises) for two sets of 16–25 repetitions at 40–60% one repetition maximum.32</td>
<td><strong>Group</strong> Gentle Hatha and Restorative yoga classes, 75–90 minutes/session, two sessions/week for 4–12 weeks.59,70</td>
</tr>
<tr>
<td><strong>Neurotoxicity</strong></td>
<td></td>
<td><strong>During chemotherapy:</strong> unsupervised low- to moderate-intensity walking and resistance exercises 7 days/week at 60–85% heart rate reserve and 3–5 out of 10 perceived exertion for 6 weeks during chemotherapy. Walking began at the patient’s pre-chemotherapy steps/day and patients were encouraged to increase by 5–20% each week (patients tracked steps using a provided pedometer). Ten upper- and lower-body resistance exercises progressed in volume to a maximum of four sets of 15 repetitions and progressed in resistance using provided TheraBand resistance bands (red, green, and blue) over 6 weeks.34</td>
<td><strong>Group</strong> Gentle Hatha and Restorative yoga classes, 75–90 minutes/session, two sessions/week for 4–12 weeks.59,70</td>
</tr>
<tr>
<td><strong>Sleep</strong></td>
<td><strong>Disturbances</strong></td>
<td><strong>During chemotherapy:</strong> supervised aerobic exercise (choice of cycling, treadmill, elliptical, rower, or combination) three sessions/week for 50–60 minutes/session starting 1–2 weeks before chemotherapy until 3–4 weeks after completion of chemotherapy. Intensity started at 55–60% VO2max and progressed to 70–75% VO2max by week 6. Initial duration started at 15–30 minutes/session and progressed to 50–60 minutes/session by week 6.30</td>
<td><strong>During radiation:</strong> supervised physical therapy exercises for core strength (abdominals, hips, back) to relieve spinal bone pain.51,54</td>
</tr>
</tbody>
</table>
in both adjuvant and palliative chemotherapy settings, high-intensity resistance, aerobic, and relaxation exercise improved VO2\text{max} by 10.7% compared to usual care, which showed no change.29 Another study in 301 patients with breast cancer (the Combined Aerobic and Resistance Exercise [CARE] trial) showed that high-dose aerobic exercise (50–60 minutes/session, three sessions/week) increased VO2\text{max} more than low-dose aerobic exercise (25–30 minutes/session, 3 sessions/week).30

Both low- and high-intensity exercise interventions are effective in reducing pain in patients receiving chemotherapy, according to results from the PACES trial.22 Aerobic exercises may be particularly effective for pain control in patients receiving chemotherapy, as suggested by the 301 patients with breast cancer in the CARE trial, showing that high-dose aerobic exercise reduced pain more than combined aerobic plus resistance exercise.30 Cognitive impairment was improved by exercise in at least two studies. One was an RCT of 479 patients receiving chemotherapy comparing unsupervised low–moderate intensity walking and resistance exercise, when compared to usual care for 6 weeks.31 Another was an RCT of 48 patients receiving myeloablative chemotherapy followed by autologous stem cell transplant, wherein subjects were randomized to 40 minutes/day of ergometric and resistance exercises, had lower rates of cognitive impairment and exhibited better psychosocial function compared to patients in the physiotherapy control condition.32

For chemotherapy-induced peripheral neuropathy (CIPN), exercise significantly improved patient-reported numbness and tingling in an RCT comparing a 6-week unsupervised low–moderate intensity walking and resistance exercise routine to usual care in 355 patients receiving taxane-, platinum-, or vinca alkaloid-based chemotherapy.33,34 In a separate trial of 60 patients with lymphoma receiving chemotherapy, a supervised moderate-intensity aerobic, resistance, and sensorimotor exercise intervention of 60 minutes/session, two sessions/week, significantly improved balance and reduced neuropathy symptoms compared to standard care.35

In regards to second-tier toxicities patients may experience while receiving chemotherapy (Table 1), aerobic and/or resistance exercise has been shown to improve sleep36 and self-esteem.37,38 however, several studies have demonstrated no improvement in depression and anxiety.27,38

### Exercise during radiation therapy

Several RCTs have shown that many forms of exercise reduce fatigue during radiation treatment in patients with breast cancer39–41 and patients with prostate cancer.39–44 One study tested supervised moderate-intensity aerobic exercise for three sessions/week, at 50–60% VO2\text{max} using a cycle ergometer, treadmill, or elliptical; or supervised moderate-intensity resistance exercise for three sessions/week, with 10 exercises, at 60–70%, of their one-repetition maximum (independently tested) versus usual care, for 24 weeks, in 121 patients with prostate cancer.45 Another study tested yoga versus brief supportive therapy for 60 minutes/session, 3–7 sessions/week, for 6 weeks in 80 patients with breast cancer.46 Exercise RCTs have also shown improvements in cardiovascular fitness during radiation treatment in patients with breast cancer (e.g. 46 patients randomized to supervised moderate-intensity cycling or usual care control; 20 patients randomized to unsupervised moderate-intensity walking or placebo stretching control),46,47 whereas some studies have shown no effects (e.g. 126 patients randomized to unsupervised home-based walking or usual care).48 The null findings from Griffith et al.48 might have been because the exercise dose was insufficient (e.g., intensity was too low), as the other studies tracked exercise intensity objectively, using heart rate monitors.

In one study examining cardiovascular fitness in patients with breast cancer receiving radiation therapy, 7 weeks of aerobic exercise increased VO2\text{max} red blood cell count, and hemoglobin count, whereas patients randomized to the placebo stretching group became worse on all three measures.49 These results show that not only can exercise protect against treatment-induced toxicities, but exercise can actually improve cardiovascular fitness during cancer treatments.

The treatment of radiation-induced pain with exercise is also well-studied, with several RCTs showing benefits.50–52 One study in 60 patients showed that 2 weeks of resistance training, performed during radiation therapy, reduced patient-reported pain and opiate medication use both 3 months and 6 months after completion of radiation treatment, compared to passive physical therapy control.50 The use of exercise to treats cognitive impairment and neurotoxicity from radiation has not been well studied in humans, but several RCTs in animal models have shown that exercise protected against radiation-induced cognitive impairment when radiation was delivered to the brain.53 RCTs in humans have shown that exercise is effective for many second tier radiation-induced toxicities as well, including sleep problems (e.g. insomnia),54 bone damage (e.g. sparing radiation-induced bone loss in patients with bone metastases),55 metabolic toxicity (e.g. reducing appetite loss),55 and psychological distress (e.g. reducing negative effects and anxiety).56,57

### Exercise during hormonal therapy

During treatment with aromatase inhibitors, exercise has proven helpful in reducing joint pain,58,59 bone pain,60,61 and bone damage,62,63 and exercise has been suggested to treat cognitive impairment based on successful treatments in animal models58 in men receiving androgen deprivation.
therapy for prostate cancer, an RCT of 155 patients demonstrated that a 12-week resistance exercise routine improved fatigue, quality of life, and upper and lower body muscular fitness, when compared to usual care, although no improvement was seen in weight, body mass index, or waist circumference.63

Exercise after completion of cancer treatment (survivorship)

A growing body of evidence suggests that exercise is safe and effective in reducing toxicities experienced after completion of cancer treatments (right column of Table 3). As reviewed below, studies have tested aerobic exercise, combined aerobic and resistance exercise, and mindfulness-based exercise.

Aerobic exercise

One RCT in 86 breast cancer survivors showed that a 12-week unsupervised low–moderate intensity, home-based walking program, significantly reduced fatigue and exhibited a trend toward improving overall mood and body esteem.64 Another RCT in 116 lung cancer survivors who walked 3 days/week for 40 minutes/day with weekly counseling, improved their anxiety and depression levels.61

Combined walking and strength training

An RCT in 66 patients with stage IV lung or colorectal cancer post-treatment showed that an 8-week home-based resistance band exercise program, combined with incremental walking, improved the mobility, fatigue, and sleep quality compared to usual care.65 In another study, a 12-month exercise program (6 months of supervised aerobic and resistance exercise, followed by 6 months of home-based exercise maintenance) improved the physical function and health-related quality of life in 100 older long-term prostate cancer survivors compared to the physical activity education control condition.67

Mindfulness-based exercise

Several studies have investigated the effects of yoga on cancer-related toxicities such as sleep disturbances,64,65 fatigue,64,66,67 psychological distress,68 cognitive impairment,69 musculoskeletal symptoms,70 and menopausal symptoms.71 An RCT of yoga in 410 cancer survivors, compared standard care to standard care plus a 4-week program called Yoga for Cancer Survivors (YOCAS©), which includes breathing exercises, postures, and meditation for 75 minutes/session, two sessions/week for 4 weeks.72 YOCAS significantly improved sleep quality,65 fatigue,64 global side-effect burden,66 memory difficulties,70 and musculoskeletal pain and discomfort,70 compared to standard care. A separate RCT comparing 12 weeks of iyengar yoga for 90 minutes/session, two sessions/week, to health education among 31 breast cancer survivors showed that yoga reduced fatigue and depression.67

Another study in 37 breast cancer survivors, showed that an 8-week yoga program consisting of postures, breathing exercises, meditation, study of pertinent topics, and group discussion for 120 minutes/session, one session/week, significantly improved sleep disturbance, fatigue, and menopausal symptoms (e.g. hot flash, joint pain, menopause-related distress), compared to wait-list control.73 Several studies of one RCT in 21 breast cancer survivors demonstrated that a 12-week Tai Chi intervention performed for 60 minutes/session, three sessions/week, improved aerobic capacity, muscular strength, flexibility, body composition, self-esteem, quality of life,74–76 and bone health (increases in bone formation, decreases in bone resorption), compared to psychosocial support control.74

Biological mechanisms of toxicities and the effects of exercise

Although a complete review of mechanisms of exercise is out of the scope of this review, we highlight several biological mechanisms involved in toxicities from cancer and its treatment as well as the effects of exercise. These pathways include inflammation,36 endocrine hormones,9,10 the HPA axis,11,12 and mitochondria.36 Exercise can exert beneficial effects on all of these pathways simultaneously, partially explaining how exercise can have widespread beneficial effects on several cancer- and treatment-related toxicities.

It is well known that the immune system, including multiple inflammatory signaling pathways, is adversely affected by cancer,75 chemotherapy,76,77 radiation,78,79 and surgery.80 Although inflammation can be part of the healthy healing process, excessive chronic inflammation might lead to fatigue,80,81 pain,82 cognitive impairment,83 neuropathy84,85 sleep disturbances,86 bone damage,87 metabolic toxicities (muscle wasting, cachexia),88,89 and psychological distress (anxiety, depression).89,90 Inflammation is mediated by an array of small proteins called cytokines, which act as inter-cellular signals that are secreted by various tissues in response to foreign invaders, ingested foods/drugs, stress, exercise, etc. Cytokines circulate in the blood and then bind to cell-surface receptors, whose activation triggers cascades of genetic and biochemical events related to the cell cycle, immune function, and inflammation.91,92 Inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α), interleukin-1 receptor antagonist (IL-1RA), and interleukin (IL)-6 have been implicated in the development of cancer-related fatigue,81 cancer-related depression and anxiety (along with IL-8),81 and cancer cachexia.93,94,95 Chronic immune activation leads to dysfunction of the endocrine system, HPA axis, mitochondria,65 and dysregulation in the secretion of pro-inflammatory cytokines.96,97 The systemic effect of chronic immune activation adversely alters hormone release, cell respiration, and ultimately skeletal muscle synthesis and function, which may alter production of ghrelin and reactive oxygen species.

Ghrelin is a peptide hormone that is an endogenous ligand to the hypothalamic growth hormone (GH) secretagogue receptor (i.e. binding of ghrelin to this receptor induces the release of GH).98 GH release increases the amount of circulating insulin-like growth factor 1 (IGF-1)99 which, when bound to its receptor IGF-1R, signals the phosphatidylinositol-3 kinase (PI3K)/Akt pathway. Mammalian target of rapamycin (mTOR), the downstream target of the PI3K/protein kinase B (Akt) pathway, is phosphorylated and thus increases protein synthesis and inhibits protein degradation.100 Dysfunction of the endocrine system and HPA axis might interfere with this pathway, thus contributing to major cancer- and treatment-related metabolic toxicities.

Mitochondrial abnormalities that lead to oxidative stress, caused by increases in reactive oxygen species, have been linked to distress (e.g. depression) and muscle wasting.95–97 Depression involves dysregulation of monoamine neurotransmitters such as serotonin and norepinephrine, and hypersensitivity of the HPA axis.101 Specifically, research suggests that alterations in these pathways are related to an enhanced inflammatory response.98,99,100 Exercise is a promising treatment for many cancer-related toxicities because exercise affects multiple biological pathways. In particular, exercise has potent and well-studied anti-inflammatory effects.6 During exercise, IL-6 is released by contracting muscles in healthy individuals.
as well as cancer patients. This pro-inflammatory cytokine exerts anti-inflammatory effects by inhibiting the production of TNF-α and IL-1 and increasing production of anti-inflammatory IL-10. Progressive resistance training has also been shown to upregulate transcription factors that increase muscle protein synthesis through the phosphorylation of mTOR. Indeed, both resistance and endurance training are capable of reducing disease-induced muscle proteolysis through enhanced phosphorylation of Akt and the Forkhead transcription factor (FoxO1). Phosphorylation of FoxO1 prevents its relocation into the nucleus where it upregulates the transcription of atrophy genes. Thus, the beneficial effects of exercise on fatigue, cardiotoxicity, pain, cognitive impairment, neurotoxicity, etc., as discussed previously, might occur partly through exercise-induced changes in inflammation.

Health disparities in cancer and exercise research
Underserved cancer patients and survivors are less likely to be physically active at every stage of the cancer continuum. Underserved individuals in this context include racial and ethnic minorities (African Americans, Hispanics, and Asian Americans) and vulnerable populations (low socioeconomic status, low educational attainment, those residing in rural communities, sexual and gender minorities, geriatrics). Racial minority patients with breast cancer are less likely to participate in physical activity after a diagnosis and their participation in exercise declines during treatment. Cancer survivors are more like to be physically active if they are white (52% were active) or Asian-American (48%) versus Hispanic (39%) or African-American (32%). Studies have also found that physical activity participation rates are very low for cancer patients who live in rural communities.

Both structural and personal barriers limit physical activity in underserved populations. Structural barriers include neighborhood or community safety concerns, lack of sidewalks and physical activity facilities, and lack of physically active role models. Socioeconomic stratifications affect health outcomes and quality of life of underserved cancer patients and they perpetuate disparities in who decides to exercise. Personal barriers to exercise include lack of time, lack of motivation, tiredness/fatigue, lack of knowledge, health conditions, physical appearance concerns, cost of facilities, and lack of social support. Additionally, most cancer patients report that they do not discuss exercise with their oncologist or primary care physician as part of their cancer treatments, despite the patient’s interest in learning more about exercise, and despite the fact that exercise adherence is increased if clinicians are involved in making recommendations for exercise. This leaves significant room for improvement to help patients initiate and adhere to an exercise program. Notwithstanding those barriers, underserved individuals can benefit from exercise to manage toxicities from cancer and its treatment.

Clinicians can have a significant impact on initiating and adhering to an exercise program, especially for underserved patients. Physicians should recognize that underserved cancer patients are less likely to exercise, so they can be proactive in their discussions with patients. To reach underserved populations, physicians can network and partner with their communities and stakeholders (e.g., churches, gyms). Partnering with their communities will not only build a mutual respect and trust especially among the underserved communities but will also provide physicians opportunities to educate other members of the community about exercise and cancer care. Of course, education alone will likely not change a patient’s exercise behavior; support and resources from the community and clinical team are crucial to improvement. For example, patient navigators can provide assistance to patients who may need transportation or child care. In addition, the combined efforts from local government, federal government, community health centers, community members, and law enforcement should ensure safe neighborhoods, install sidewalks, and improve access to exercise facilities with reduced or free cost for individuals in need.

Technology to enhance exercise tracking and adherence
Mobile technology is a rapidly developing and promising way to help patients exercise more by tracking their exercise and providing feedback to enhance motivation and adherence. Nearly two-thirds of adults in the United States own a smartphone and technological advancements have enabled these devices to monitor health behaviors and provide convenient feedback. Wearable digital activity trackers have similar capabilities but may have more consumer appeal than a smartphone. Some of these devices are fairly accurate for measuring steps walked, with one study showing wrist-worn activity trackers underestimating steps by 1–23%. Smartphone applications underestimate steps by 6–7%, and pedometers overestimating steps by up to a mere 1%. However, for obtaining heart rate data, the current generation of wrist-worn activity trackers do not perform well, with one study showing 95% of estimated heart rate values varying by 30 beats per minute under or over the gold-standard electrocardiogram.

Mobile devices are also being incorporated into behavioral interventions in an approach called mobile health, or mHealth. This new breed of interventions utilize mobile computing and communication technologies for a range of functions, such as clinical decision support systems, data collection tools for healthcare professionals, and supporting health behavior change for management of chronic diseases such as obesity and diabetes. The use of mobile health interventions is a rapidly expanding area of research and practice, and has only recently been applied to cancer patients and survivors. Next, we review the use of mobile behavioral interventions in the general population and in cancer patients specifically.

Mobile health behavioral interventions in the general population
In healthy adults, dozens of studies have suggested that the use of a pedometer, a relatively minimalist mobile health intervention, significantly increases physical activity, decreases body mass index, and decreases blood pressure. Short-term studies have shown that more rigorous mobile health behavioral intervention results in modest improvements in weight loss in the general population. Recently, an RCT entitled Innovative Approaches to Diet, Exercise, and Activity (IDEA) examined the effectiveness of pedometers for long-term health behavior modifications. At the beginning of the study, all participants were prescribed a low-calorie diet and physical activity program, with group counseling sessions. At 6 months, they were randomized to either the standard intervention group, which utilized self-monitoring of diet and physical activity using a website, or the enhanced intervention group, which utilized digital activity trackers and accompanying web interface to monitor diet and physical activity. While both groups had significant improvements in body composition, fitness, physical activity, and diet, these improvements were not statistically significantly different between the two groups. Furthermore, among adults with a relatively high body mass index of 25–40 kg/m², integration of digital
activity trackers to a standard clinical intervention resulted in less weight loss over 24 months. However, the use of digital activity trackers was not initiated until 6 months after the onset of intervention, which may have hindered how the technology was used.

**Mobile health behavioral interventions among cancer patients and survivors**

A recent systematic review examined interactive web-based interventions that aimed to increase patient empowerment and physical activity for various chronic conditions in the general population. 150 This review identified seven elements that can be translated into mobile health recommendations for cancer survivors: education, self-monitoring, feedback/tailored information, self-management training, personal exercise program, and communication with either healthcare providers or patients (e.g., chat, email). These essential components may serve as the foundation for designing future interactive mobile health interventions for cancer survivors, with the ultimate goal to improve their health status and quality of life. Importantly, two recent studies demonstrated feasibility and improved physical activity levels from two mobile health interventions: a 6-week, web-based, behavioral modification program for adult cancer survivors, 23 and a technology-based, 6-month lifestyle intervention via either telemedicine or text messaging, for patients with endometrial cancer. 151

**Suggestions for clinicians**

A growing body of evidence shows that exercise is safe, feasible, and effective to ameliorate several side effects of cancer and its treatments along the cancer treatment continuum. Our six principles and clinical suggestions are summarized in Table 2. The literature provides best practice suggestions for clinicians to prescribe exercise for treating or preventing certain toxicities, but does not yet provide definitive guidelines in terms of exercise type, frequency, intensity, and duration for all toxicities.

Prior research has provided an excellent starting point for the dose of exercise recommended for cancer patients, including special considerations and suggested modifications. 6,7 The American College of Sports Medicine indicates cancer patients and survivors should slowly progress to 150 minutes/week of moderate-intensity aerobic exercise, or 75 minutes/week of vigorous intensity exercise, combined with 2–3 days of strength training across all major muscle groups, plus regular stretching. 8 Higher-intensity exercise has been shown to be more effective for certain toxicities (e.g., cardiotoxicity, 9 fatigue) 10 but only if that exercise is feasible. 21 These results are consistent with the idea of an inverted-U association between exercise response and exercise dose (training intensity, session duration), suggested in reviews of exercise in relation to cancer toxicities, 12 cancer mortality, 16 heart disease, 17 and healthy aging 18 (i.e. a moderate dose exercise is best). Thus, exercise recommendations should be started slowly and, optimally, individualized with the help of an exercise professional who is familiar with the needs of cancer patients. Table 3 lists specific exercise regimens shown to be beneficial in an RCT.

**Conclusions**

The advent of improved cancer screening techniques and new anti-neoplastic therapies have led to improved overall survival for patients with cancer over the past 20 years. Additionally, patients living with cancer can be more active due, in part, to improvements in supportive care and clinical trials that have challenged the concept of over-treatment. These phenomena have opened the door to studying the utility of exercise in patients with cancer on treatment and cancer survivorship. Biological mechanisms of both cancer and its treatments, specifically chemotherapy, radiation, and hormonal therapy, that lead to inflammation, muscle breakdown, and functional limitations can be targeted using exercise. Furthermore, clinical trials suggest that exercise can treat many high-priority toxicities (Table 1)—namely fatigue, cardiotoxicity, pain, cognitive impairment, neurotoxicity, sleep disturbances, bone damage, metabolic toxicity, and psychological distress—sometimes before, during, and after cancer treatment (example exercise regimens in Table 3). The development of wearable activity trackers and mHealth interventions has enhanced our ability to measure patient activity, and how it may affect cancer and treatment-related toxicities. Many of these studies include low-cost, home-based interventions that are convenient and achievable in these populations. Despite the seemingly accessible nature of exercise, disparities still exist in employing the use of exercise in underserved communities. As the multitude of benefits of exercise in patients with cancer continue to come forth, it is important for healthcare providers and community leaders to address and remove barriers that patients may face so interventions like exercise can reach and help more and more patients each day.

---

Review

Supportive Oncology


pedometers to increase physical activity and improve health: a systematic review. JAMA. 2007;298:2296–304.